Patent ID: 7604952
Filing Date: 2009-10-20
Classification: G01N,Y10S,Y10T

Abstract:
1. A method for diagnosing coronary artery disease comprising performing steps (a), (c), and (e) and at least one of steps (b) and (d): (a) obtaining one or more human samples comprising whole blood or a fluid derived from whole blood; (b) comparing a level of oxidized low density lipoprotein (OxLDL) having at least 60 aldehyde-modified lysine residues per apolipoprotein B-100 (apo B-100) moiety in one of the one or more human samples to the level of the OxLDL in a control; (c) comparing a level of malondialdehyde-modified low density lipoprotein (MDA-modified LDL) having at least 60 aldehyde-modified lysine residues per apolipoprotein B-100 (apo B-100) moiety in one of the one or more human samples to the level of the MDA-modified LDL in a control; (d) comparing a level of a heart protein that is a marker for acute myocardial infarction in one of the one or more human samples to the level of the heart protein in a control; and (e) making a diagnosis based on results from step (c) and at least one of steps (b) and (d) from the following matrix if steps (b), (c), and (d) are all performed: or making a diagnosis based on results from step (c) and at least one of steps (b) and (d) from the following matrix if steps (b) and (c) are performed: or making a diagnosis based on results from step (c) and at least one of steps (b) and (d) from the following matrix if steps (C) and (d) are performed: wherein “+” indicates that the level of the OxLDL, MDA-modified LDL, and heart protein in the human sample is higher compared to the level of the OxLDL, MDA-modified LDL, and heart protein in the control and “−” indicates that the level of the OxLDL, MDA-modified LDL, and heart protein in the human sample is not higher compared to the level of the OxLDL, MDA-modified LDL, and heart protein in the control, the control providing results based on those of a normal control population.